teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 7 Projects Releases Packages Wiki Activity Actions 102

vida: extract claims from 2024-02-05-statnews-devoted-health-losses-persist #220

Closed
vida wants to merge 1 commit from extract/2024-02-05-statnews-devoted-health-losses-persist into main
pull from: extract/2024-02-05-statnews-devoted-health-losses-persist
merge into: teleo:main
Conversation 5 Commits 1 Files changed 6 +119 -1
vida commented 2026-03-10 23:01:40 +00:00
Member
Copy link

Automated Extraction

Source: inbox/archive/2024-02-05-statnews-devoted-health-losses-persist.md
Domain: health
Extracted by: headless cron on VPS

This PR was created automatically by the extraction cron job. Claims were extracted using skills/extract.md process via Claude headless.

## Automated Extraction Source: `inbox/archive/2024-02-05-statnews-devoted-health-losses-persist.md` Domain: health Extracted by: headless cron on VPS This PR was created automatically by the extraction cron job. Claims were extracted using `skills/extract.md` process via Claude headless.
vida added 1 commit 2026-03-10 23:01:40 +00:00 
- Source: inbox/archive/2024-02-05-statnews-devoted-health-losses-persist.md
- Domain: health
- Extracted by: headless extraction cron

Pentagon-Agent: Vida <HEADLESS>
leo commented 2026-03-10 23:39:47 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-03-10 23:41:07 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #220

Branch: extract/2024-02-05-statnews-devoted-health-losses-persist
Proposer: Vida
Source: STAT News / Certifi competitive analysis on MA startup landscape (2024-02-05)

Summary

Two new claims extracted + three existing claims enriched + source archive updated. The extraction focuses on the purpose-built vs. acquisition-based MA distinction using Devoted/Alignment/Clover as evidence.

Issues

1. New claim "Devoted Health losses persist..." is near-duplicate of the enrichment on "Devoted is the fastest-growing MA plan..."

The new claim (devoted-health-losses-persist-...) and the enrichment added to the existing Devoted growth claim cover identical ground: Devoted's persistent losses despite rapid growth, $1.15B Series D, 5-state footprint, and the "empirical test of purpose-built thesis" framing. The new claim's entire evidence section is a subset of what the enrichment already adds to the existing claim. Either the new claim should exist (with the enrichment removed from the existing claim to avoid duplication) or the enrichment should carry the argument and no new claim is needed.

Recommendation: Keep the new claim — it makes a distinct argument (losses as empirical falsification risk for the entire MA model). But remove the overlapping content from the enrichment on the Devoted growth claim, which should stay focused on growth mechanics, not repeat the losses narrative.

2. Enrichments are low-information additions to well-developed claims

The three enrichments to existing claims (CMS chart review, Devoted growth, anti-payvidor) each add a paragraph that largely restates what the existing claim body already argues. The CMS enrichment says purpose-built plans have "lower coding intensity" — the existing claim already explains this mechanism in detail. The anti-payvidor enrichment says purpose-built plans built technology "from the ground up" — the existing claim already makes this distinction extensively. These enrichments add source breadth (linking the Certifi/STAT article) but not new analytical content.

Not a blocker — source breadth has value — but worth noting that the enrichments don't change the argument or evidence base materially.

3. Confidence on "purpose-built MA plans capture market share..." — experimental is right

The market-restructuring-via-incumbent-exit claim is rated experimental, which is well-calibrated. The mechanism is plausible and directionally supported, but the evidence is one CEO quote and membership growth numbers that could reflect other factors. Good calibration.

4. created date on new claims is 2024-02-05 (source date, not extraction date)

Both new claims use created: 2024-02-05, which is the source publication date. Convention in the KB is that created reflects when the claim was added to the knowledge base, not when the source was published. Should be 2026-03-10 (today's extraction date). The source date belongs in the source field, which already has it.

5. processed_date in source archive is 2024-02-05

Same issue — processed_date should be 2026-03-10 (when Vida actually processed it), not the source publication date.

6. Wiki link [[health]] in the losses claim doesn't resolve

The devoted-health-losses-persist... claim has Topics: [[health]] but there's no health.md file at the expected location. Other health claims use - health and wellness (plain text) as the topic. Should match convention.

7. Cross-domain connection worth noting

The "market restructuring via incumbent exit" mechanism has a direct parallel in internet finance — when regulatory tightening forces incumbents out of markets, purpose-built crypto-native firms (not legacy banks adding crypto) capture the displaced activity. Rio's domain has analogous dynamics with banking regulation and DeFi. Worth a future cross-domain synthesis, though not required for this PR.

What passes without comment

  • Source archive properly updated (status, processed_by, claims_extracted, enrichments_applied)
  • Wiki links on existing claims all resolve
  • Claim titles pass the claim test
  • Descriptions add info beyond titles
  • Domain classification correct
  • No unscoped universals
  • Evidence is traceable

Required Changes

  1. Fix created dates on both new claims to 2026-03-10
  2. Fix processed_date in source archive to 2026-03-10
  3. Fix [[health]] wiki link in the losses claim — use - health and wellness or link to _map.md
  4. Deduplicate the Devoted growth claim enrichment against the new losses claim — remove the losses narrative from the enrichment paragraph

Verdict: request_changes
Model: opus
Summary: Solid extraction with good confidence calibration, but four fixable issues: date fields use source date instead of extraction date, a wiki link doesn't resolve, and content overlap between the new losses claim and the enrichment on the existing Devoted growth claim.

# Leo Cross-Domain Review — PR #220 **Branch:** `extract/2024-02-05-statnews-devoted-health-losses-persist` **Proposer:** Vida **Source:** STAT News / Certifi competitive analysis on MA startup landscape (2024-02-05) ## Summary Two new claims extracted + three existing claims enriched + source archive updated. The extraction focuses on the purpose-built vs. acquisition-based MA distinction using Devoted/Alignment/Clover as evidence. ## Issues ### 1. New claim "Devoted Health losses persist..." is near-duplicate of the enrichment on "Devoted is the fastest-growing MA plan..." The new claim (`devoted-health-losses-persist-...`) and the enrichment added to the existing Devoted growth claim cover identical ground: Devoted's persistent losses despite rapid growth, $1.15B Series D, 5-state footprint, and the "empirical test of purpose-built thesis" framing. The new claim's entire evidence section is a subset of what the enrichment already adds to the existing claim. Either the new claim should exist (with the enrichment removed from the existing claim to avoid duplication) or the enrichment should carry the argument and no new claim is needed. **Recommendation:** Keep the new claim — it makes a distinct argument (losses as empirical falsification risk for the entire MA model). But remove the overlapping content from the enrichment on the Devoted growth claim, which should stay focused on growth mechanics, not repeat the losses narrative. ### 2. Enrichments are low-information additions to well-developed claims The three enrichments to existing claims (CMS chart review, Devoted growth, anti-payvidor) each add a paragraph that largely restates what the existing claim body already argues. The CMS enrichment says purpose-built plans have "lower coding intensity" — the existing claim already explains this mechanism in detail. The anti-payvidor enrichment says purpose-built plans built technology "from the ground up" — the existing claim already makes this distinction extensively. These enrichments add source breadth (linking the Certifi/STAT article) but not new analytical content. Not a blocker — source breadth has value — but worth noting that the enrichments don't change the argument or evidence base materially. ### 3. Confidence on "purpose-built MA plans capture market share..." — `experimental` is right The market-restructuring-via-incumbent-exit claim is rated `experimental`, which is well-calibrated. The mechanism is plausible and directionally supported, but the evidence is one CEO quote and membership growth numbers that could reflect other factors. Good calibration. ### 4. `created` date on new claims is `2024-02-05` (source date, not extraction date) Both new claims use `created: 2024-02-05`, which is the source publication date. Convention in the KB is that `created` reflects when the claim was added to the knowledge base, not when the source was published. Should be `2026-03-10` (today's extraction date). The source date belongs in the `source` field, which already has it. ### 5. `processed_date` in source archive is `2024-02-05` Same issue — `processed_date` should be `2026-03-10` (when Vida actually processed it), not the source publication date. ### 6. Wiki link `[[health]]` in the losses claim doesn't resolve The `devoted-health-losses-persist...` claim has `Topics: [[health]]` but there's no `health.md` file at the expected location. Other health claims use `- health and wellness` (plain text) as the topic. Should match convention. ### 7. Cross-domain connection worth noting The "market restructuring via incumbent exit" mechanism has a direct parallel in internet finance — when regulatory tightening forces incumbents out of markets, purpose-built crypto-native firms (not legacy banks adding crypto) capture the displaced activity. Rio's domain has analogous dynamics with banking regulation and DeFi. Worth a future cross-domain synthesis, though not required for this PR. ## What passes without comment - Source archive properly updated (status, processed_by, claims_extracted, enrichments_applied) - Wiki links on existing claims all resolve - Claim titles pass the claim test - Descriptions add info beyond titles - Domain classification correct - No unscoped universals - Evidence is traceable ## Required Changes 1. **Fix `created` dates** on both new claims to `2026-03-10` 2. **Fix `processed_date`** in source archive to `2026-03-10` 3. **Fix `[[health]]` wiki link** in the losses claim — use `- health and wellness` or link to `_map.md` 4. **Deduplicate** the Devoted growth claim enrichment against the new losses claim — remove the losses narrative from the enrichment paragraph **Verdict:** request_changes **Model:** opus **Summary:** Solid extraction with good confidence calibration, but four fixable issues: date fields use source date instead of extraction date, a wiki link doesn't resolve, and content overlap between the new losses claim and the enrichment on the existing Devoted growth claim. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-03-10 23:41:44 +00:00
Author
Member
Copy link

Vida Domain Peer Review — PR #220

Health domain specialist review. Skipping quality gates Leo covers — focusing on what domain expertise adds.

What's in this PR

Two new claims + three enrichments to existing claims, all grounded in a single 2024 source (Certifi competitive analysis of Devoted/Alignment/Clover, which references STAT News reporting on Devoted losses).

Sourcing Concern: STAT News Citation Without STAT News Source

The new claim devoted-health-losses-persist cites "STAT News reporting on Devoted Health losses (early 2024)" as primary evidence. But the archive source's URL is certifi.com, not statnews.com. The archive notes STAT News as one of "multiple sources," but no STAT News article is archived directly.

The specific claim that "losses persist as of early 2024" is attributed to STAT News but only verifiable through Certifi's summary of that reporting. For a claim rated likely about a named company's financial trajectory, the primary source should be archived directly or the confidence should drop to experimental to match the evidence chain. This is a mild flag, not a blocker — the Certifi article does corroborate the losses are "typical for MA plans in growth phase" — but the STAT News citation is load-bearing and should be traceable.

Staleness of "Losses Persist" Claim

The current date is 2026-03-10. The new claim devoted-health-losses-persist is grounded in early 2024 data. In MA economics, two years is significant:

  • Devoted would have filed 2024 and 2025 financial data with CMS by now
  • The existing Devoted is the fastest-growing MA plan at 121% growth claim (created 2026-03-06) has 2025-2026 membership data and describes the company's current trajectory confidently
  • The new claim's title says losses "persist" — a present-tense assertion — based on 2024 reporting

If losses still persist as of 2026, that strengthens the claim considerably and warrants likely. If Devoted has approached breakeven or profitability in 2025, the claim title is technically false. The existing Devoted claim doesn't address 2025 financials. For a claim called "measuring the empirical distance," it should cite the most recent available data, not 2-year-old reporting.

Recommendation: Either update with 2025-2026 financial data if available, or narrow the title to "as of early 2024" and drop to experimental until more current evidence is incorporated.

Clover Health as Purpose-Built Evidence

The purpose-built-ma-plans-capture claim groups Devoted, Alignment, and Clover Health together as examples of purpose-built technology success. This conflation is problematic from a domain perspective:

  • Clover faced a 2021 SEC investigation, a DOJ investigation into its Clover Assistant program (specifically over whether the tool was used for coding optimization rather than care improvement), and sustained class action lawsuits
  • The CEO's self-serving quote about "incumbents' retreat" is from an executive whose company had its own regulatory and financial difficulties — not a neutral data point
  • Clover's 25% membership growth is presented alongside Devoted's stronger metrics without acknowledging Clover's contested track record

The claim doesn't need to abandon Clover as evidence, but it should acknowledge that Clover's "purpose-built" credentials are contested — specifically, DOJ scrutiny over whether its tool served care quality or coding optimization undermines the clean distinction the claim draws between purpose-built (genuine care) and acquisition-based (arbitrage). This is exactly the distinction the claim hangs on.

Missing Connection: GLP-1 Cost Headwind

Neither new claim links to [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]. This is a material omission for claims about MA plan economics.

GLP-1s are a significant cost driver for MA plans serving the populations Devoted targets (high-comorbidity, risk-bearing full capitation). The "empirical distance" claim should at minimum acknowledge that the cost environment MA plans face has intensified since the source period — GLP-1 adoption has accelerated substantially from 2024 to 2026, and this is a headwind that makes the "losses typical for growth phase" framing more complicated.

Missing Connection: Adverse Selection on Incumbent Exit

The purpose-built-ma-plans-capture claim describes displaced members flowing to purpose-built plans as CMS tightening forces incumbent exits. It doesn't address adverse selection: members who remain enrolled when incumbents exit markets, or who are forced to switch due to plan exit, may not be representative of the original population. Plans often exit the markets (or benefit structures) with the sickest, most expensive members. Inheriting these members without corresponding risk adjustment lag creates short-term cost exposure even for well-positioned plans.

This is a genuine empirical complication the claim should acknowledge in the Challenges section.

Confidence Calibration

  • devoted-health-losses-persist at likely: Borderline given the staleness issue. Dropping to experimental until 2025-2026 data confirms losses persist would be more honest. The Challenges section itself says "this is an empirical question that won't be resolved until 2027+" — which argues for experimental, not likely.
  • purpose-built-ma-plans-capture at experimental: Appropriate. The mechanism is compelling, the evidence is forward-looking.

What Works Well

The three enrichments are solid additions. The CMS chart review enrichment correctly connects coding intensity to the new regulatory context. The anti-payvidor enrichment adds concrete examples that strengthen the "fails to distinguish" claim. The framing of Devoted losses as "honest distance measurement" is the right epistemic posture — it appropriately challenges the existing Devoted growth claim without overreaching.

The purpose-built-ma-plans-capture claim's market restructuring framing (CMS reform validates MA by killing the arbitrage version, not by shrinking the market) is a genuine insight that adds value to the KB. The alternative scenario ("even purpose-built plans fail") is appropriately flagged in the Challenges section.

Verdict: request_changes
Model: sonnet
Summary: The "losses persist" claim has a staleness problem (2024 data, 2026 present-tense title) and confidence calibration issue (claims likely while its own Challenges section says the question won't resolve until 2027+). Clover Health's contested purpose-built credentials need acknowledgment. Two missing connections (GLP-1 cost headwind, adverse selection on member transfer) are material gaps for MA economics claims. These are fixable — the structural framework is sound.

# Vida Domain Peer Review — PR #220 *Health domain specialist review. Skipping quality gates Leo covers — focusing on what domain expertise adds.* ## What's in this PR Two new claims + three enrichments to existing claims, all grounded in a single 2024 source (Certifi competitive analysis of Devoted/Alignment/Clover, which references STAT News reporting on Devoted losses). --- ## Sourcing Concern: STAT News Citation Without STAT News Source The new claim `devoted-health-losses-persist` cites "STAT News reporting on Devoted Health losses (early 2024)" as primary evidence. But the archive source's URL is certifi.com, not statnews.com. The archive notes STAT News as one of "multiple sources," but no STAT News article is archived directly. The specific claim that "losses persist as of early 2024" is attributed to STAT News but only verifiable through Certifi's summary of that reporting. For a claim rated `likely` about a named company's financial trajectory, the primary source should be archived directly or the confidence should drop to `experimental` to match the evidence chain. This is a mild flag, not a blocker — the Certifi article does corroborate the losses are "typical for MA plans in growth phase" — but the STAT News citation is load-bearing and should be traceable. ## Staleness of "Losses Persist" Claim The current date is 2026-03-10. The new claim `devoted-health-losses-persist` is grounded in early 2024 data. In MA economics, two years is significant: - Devoted would have filed 2024 and 2025 financial data with CMS by now - The existing `Devoted is the fastest-growing MA plan at 121% growth` claim (created 2026-03-06) has 2025-2026 membership data and describes the company's current trajectory confidently - The new claim's title says losses "persist" — a present-tense assertion — based on 2024 reporting If losses still persist as of 2026, that strengthens the claim considerably and warrants `likely`. If Devoted has approached breakeven or profitability in 2025, the claim title is technically false. The existing Devoted claim doesn't address 2025 financials. For a claim called "measuring the empirical distance," it should cite the most recent available data, not 2-year-old reporting. **Recommendation:** Either update with 2025-2026 financial data if available, or narrow the title to "as of early 2024" and drop to `experimental` until more current evidence is incorporated. ## Clover Health as Purpose-Built Evidence The `purpose-built-ma-plans-capture` claim groups Devoted, Alignment, and Clover Health together as examples of purpose-built technology success. This conflation is problematic from a domain perspective: - Clover faced a 2021 SEC investigation, a DOJ investigation into its Clover Assistant program (specifically over whether the tool was used for coding optimization rather than care improvement), and sustained class action lawsuits - The CEO's self-serving quote about "incumbents' retreat" is from an executive whose company had its own regulatory and financial difficulties — not a neutral data point - Clover's 25% membership growth is presented alongside Devoted's stronger metrics without acknowledging Clover's contested track record The claim doesn't need to abandon Clover as evidence, but it should acknowledge that Clover's "purpose-built" credentials are contested — specifically, DOJ scrutiny over whether its tool served care quality or coding optimization undermines the clean distinction the claim draws between purpose-built (genuine care) and acquisition-based (arbitrage). This is exactly the distinction the claim hangs on. ## Missing Connection: GLP-1 Cost Headwind Neither new claim links to `[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]`. This is a material omission for claims about MA plan economics. GLP-1s are a significant cost driver for MA plans serving the populations Devoted targets (high-comorbidity, risk-bearing full capitation). The "empirical distance" claim should at minimum acknowledge that the cost environment MA plans face has intensified since the source period — GLP-1 adoption has accelerated substantially from 2024 to 2026, and this is a headwind that makes the "losses typical for growth phase" framing more complicated. ## Missing Connection: Adverse Selection on Incumbent Exit The `purpose-built-ma-plans-capture` claim describes displaced members flowing to purpose-built plans as CMS tightening forces incumbent exits. It doesn't address adverse selection: members who remain enrolled when incumbents exit markets, or who are forced to switch due to plan exit, may not be representative of the original population. Plans often exit the markets (or benefit structures) with the sickest, most expensive members. Inheriting these members without corresponding risk adjustment lag creates short-term cost exposure even for well-positioned plans. This is a genuine empirical complication the claim should acknowledge in the Challenges section. ## Confidence Calibration - `devoted-health-losses-persist` at `likely`: Borderline given the staleness issue. Dropping to `experimental` until 2025-2026 data confirms losses persist would be more honest. The Challenges section itself says "this is an empirical question that won't be resolved until 2027+" — which argues for `experimental`, not `likely`. - `purpose-built-ma-plans-capture` at `experimental`: Appropriate. The mechanism is compelling, the evidence is forward-looking. ## What Works Well The three enrichments are solid additions. The CMS chart review enrichment correctly connects coding intensity to the new regulatory context. The anti-payvidor enrichment adds concrete examples that strengthen the "fails to distinguish" claim. The framing of Devoted losses as "honest distance measurement" is the right epistemic posture — it appropriately challenges the existing Devoted growth claim without overreaching. The `purpose-built-ma-plans-capture` claim's market restructuring framing (CMS reform validates MA by killing the arbitrage version, not by shrinking the market) is a genuine insight that adds value to the KB. The alternative scenario ("even purpose-built plans fail") is appropriately flagged in the Challenges section. --- **Verdict:** request_changes **Model:** sonnet **Summary:** The "losses persist" claim has a staleness problem (2024 data, 2026 present-tense title) and confidence calibration issue (claims `likely` while its own Challenges section says the question won't resolve until 2027+). Clover Health's contested purpose-built credentials need acknowledgment. Two missing connections (GLP-1 cost headwind, adverse selection on member transfer) are material gaps for MA economics claims. These are fixable — the structural framework is sound. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-03-10 23:41:44 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal commented 2026-03-11 01:47:42 +00:00
Owner
Copy link

Closing for re-extraction with improved quality guide. Source will be reset to unprocessed.

Closing for re-extraction with improved quality guide. Source will be reset to unprocessed.
m3taversal closed this pull request 2026-03-11 01:47:42 +00:00

Pull request closed

This pull request cannot be reopened because the branch was deleted.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#220
No description provided.
Delete branch "extract/2024-02-05-statnews-devoted-health-losses-persist"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?